Jim Cramer spotlights Amgen and Johnson & Johnson in back-to-back takes on a market week

Jim Cramer used the Dow Jones Industrial Average’s third-quarter performance as a springboard on Oct. 1, turning the program into a quick comparative look at two major healthcare names: Amgen and Johnson & Johnson.

In the Yahoo Finance recap, Cramer first discussed Amgen Inc. (AMGN) during a segment tied to how the Dow performed in the quarter, framing the company as one of the stocks drawing his attention in the context of broader market results.

Later in the same episode, the recap says Cramer shifted to Johnson & Johnson (JNJ). The contrast was not described in detail in the available materials, but the takeaway in the coverage is that the two companies were “catch[ing]” his eye for different reasons.

The Yahoo Finance write-up does not provide the underlying specifics of what Cramer cited for either company, such as particular pipeline updates, commercial developments, guidance changes, or valuation arguments. It also does not include direct quotes or a point-by-point breakdown of the catalysts he associated with each stock.

For investors and healthcare watchers, the framing matters because JNJ and Amgen both sit in the same broad industry, but they are driven by different business mixes. Johnson & Johnson is diversified across pharmaceuticals and medical devices, while Amgen is known primarily for biotechnology-based therapeutics and related manufacturing and commercial execution.

That sector distinction is one reason a “different reasons” comparison can be meaningful: market participants often try to separate themes such as drug-cycle strength, patent and competitive pressures, regulatory momentum, and the durability of cash generation from longer-tail developments like late-stage trials or platform science.

Still, as presented in the Yahoo Finance recap, the details that typically help the market interpret a television call are missing. The post does not spell out whether Cramer’s commentary focused on near-term earnings expectations, longer-term product timelines, or risk factors, nor does it indicate any specific timeframe beyond the episode date.

What to watch next is whether subsequent company disclosures, such as quarterly earnings commentary, regulatory milestones, or pipeline and product-portfolio updates, align with the themes Cramer raised. Without those specifics in the recap itself, the most immediate value of the coverage may be in highlighting which large-cap healthcare names are on the analyst commentary radar rather than in indicating a concrete, evidence-backed catalyst.